Koen Andries
Overview
Explore the profile of Koen Andries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
5271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villellas C, Stevenaert F, Remmerie B, Andries K
Antimicrob Agents Chemother
. 2024 Mar;
68(4):e0127523.
PMID: 38470194
Multidrug-resistant tuberculosis (MDR-TB) patients not cured at the time of stopping treatment are exposed to Minimum Inhibitory Concentration (MIC) and sub-MIC levels for many months after discontinuing bedaquiline (BDQ) or...
2.
Chauffour A, Lounis N, Andries K, Jarlier V, Veziris N, Aubry A
PLoS Negl Trop Dis
. 2023 Nov;
17(11):e0011379.
PMID: 38011249
Background: Bedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal...
3.
Kaushik A, Ammerman N, Tasneen R, Lachau-Durand S, Andries K, Nuermberger E
Am J Respir Crit Care Med
. 2021 Dec;
205(5):570-579.
PMID: 34939891
Completion of preventive therapy is a major bottleneck in global tuberculosis control. Long-acting injectable drug formulations would shorten therapy administration and may thereby improve completion rates. Recently, a long-acting formulation...
4.
Kort F, Le Ray L, Chauffour A, Jarlier V, Lounis N, Andries K, et al.
Eur Respir J
. 2020 May;
56(3).
PMID: 32430417
Background: The World Health Organization recommends supervising the treatment of tuberculosis. Intermittent regimens have the potential to simplify the supervision and improve compliance. Our objective was to analyse the sterilising...
5.
Kaushik A, Ammerman N, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, et al.
Antimicrob Agents Chemother
. 2019 Feb;
63(4).
PMID: 30745396
The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective was...
6.
Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, et al.
PLoS One
. 2018 Jul;
13(7):e0200539.
PMID: 30024924
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints...
7.
Choi P, Sutherland H, Tong A, Blaser A, Franzblau S, Cooper C, et al.
Bioorg Med Chem Lett
. 2017 Nov;
27(23):5190-5196.
PMID: 29107541
Analogues of bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive...
8.
Tong A, Choi P, Blaser A, Sutherland H, Tsang S, Guillemont J, et al.
ACS Med Chem Lett
. 2017 Oct;
8(10):1019-1024.
PMID: 29057044
Bedaquiline () is a new drug for tuberculosis and the first of the diarylquinoline class. It demonstrates excellent efficacy against TB but induces phospholipidosis at high doses, has a long...
9.
Aguilar-Ayala D, Cnockaert M, Andre E, Andries K, Gonzalez-Y-Merchand J, Vandamme P, et al.
J Med Microbiol
. 2017 Jul;
66(8):1140-1143.
PMID: 28749330
Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The...
10.
Furin J, Diacon A, Andries K
Int J Tuberc Lung Dis
. 2017 Feb;
21(1):4-5.
PMID: 28157457
No abstract available.